Eriglip 20mg Tablet contains Teneligliptin 20mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, Teneligliptin enhances the levels of incretin hormones such as GLP-1 and GIP, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, thereby improving glycemic control. Eriglip is typically prescribed as an adjunct to diet and exercise to improve blood sugar levels in adults inadequately controlled by lifestyle modifications alone or in combination with other antidiabetic agents. The once-daily oral administration of Eriglip 20mg offers convenience and improved patient compliance. Clinical studies have demonstrated its efficacy in reducing HbA1c levels with a low risk of hypoglycemia and a favorable safety profile. It is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Caution is advised in patients with renal or hepatic impairment, and periodic monitoring of blood glucose and renal function is recommended. Common adverse effects may include nasopharyngitis, headache, and gastrointestinal disturbances. Eriglip 20mg should be used under medical supervision with appropriate lifestyle interventions to achieve optimal glycemic control.